This is what analysts have to say about C. R. Bard, Inc. (NYSE:BCR) after last week.

December 7, 2017 - By Adrian Mccoy

 This is what analysts have to say about C. R. Bard, Inc. (NYSE:BCR) after last week.
Investors sentiment decreased to 0.58 in 2017 Q2. Its down 0.30, from 0.88 in 2017Q1. It dropped, as 99 investors sold C. R. Bard, Inc. shares while 273 reduced holdings. 103 funds opened positions while 111 raised stakes. 55.14 million shares or 10.97% less from 61.93 million shares in 2017Q1 were reported.
Vanguard Grp Inc has invested 0.12% in C. R. Bard, Inc. (NYSE:BCR). Amica Pension Fund Board Of Trustees holds 0.18% or 4,656 shares in its portfolio. Ibm Retirement Fund owns 0.12% invested in C. R. Bard, Inc. (NYSE:BCR) for 1,771 shares. Amer Century Cos Incorporated holds 0.02% of its portfolio in C. R. Bard, Inc. (NYSE:BCR) for 65,543 shares. Swiss Bancorp owns 263,161 shares. United Kingdom-based Kames Cap Public Limited Liability Com has invested 0% in C. R. Bard, Inc. (NYSE:BCR). The North Carolina-based Captrust Advsrs has invested 0.02% in C. R. Bard, Inc. (NYSE:BCR). Engineers Gate Manager Lp holds 0.18% of its portfolio in C. R. Bard, Inc. (NYSE:BCR) for 6,306 shares. Smith Moore Communication invested in 0.08% or 780 shares. Savings Bank Of Nova Scotia reported 16,367 shares or 0.03% of all its holdings. Tiaa Cref Ltd reported 257,641 shares stake. Cetera Advisor Netwr Limited Co invested in 0.02% or 1,291 shares. The New York-based Amer Int Gru has invested 0.03% in C. R. Bard, Inc. (NYSE:BCR). Argentiere Capital Ag invested in 4.69% or 44,300 shares. Cantab Capital Partners Llp holds 0% or 1,256 shares in its portfolio.

C. R. Bard, Inc. (NYSE:BCR) Ratings Coverage

Among 15 analysts covering CR Bard (NYSE:BCR), 4 have Buy rating, 0 Sell and 11 Hold. Therefore 27% are positive. CR Bard had 32 analyst reports since August 27, 2015 according to SRatingsIntel. Jefferies maintained C. R. Bard, Inc. (NYSE:BCR) on Tuesday, September 12 with “Hold” rating. Morgan Stanley upgraded the shares of BCR in report on Tuesday, January 3 to “Overweight” rating. The firm earned “Buy” rating on Wednesday, April 12 by BMO Capital Markets. The rating was downgraded by BMO Capital Markets on Wednesday, April 26 to “Market Perform”. Cowen & Co maintained the stock with “Hold” rating in Friday, July 28 report. The firm has “Buy” rating by Citigroup given on Wednesday, July 27. The firm has “Buy” rating by Evercore given on Thursday, September 15. Jefferies maintained C. R. Bard, Inc. (NYSE:BCR) on Wednesday, July 27 with “Hold” rating. On Monday, September 7 the stock rating was downgraded by Zacks to “Hold”. The company was initiated on Thursday, November 12 by Citigroup. Below is a list of C. R. Bard, Inc. (NYSE:BCR) latest ratings and price target changes.

06/11/2017 Broker: Barclays Capital Rating: Equal-Weight Old Target: $245 New Target: $337 Maintain
11/10/2017 Broker: BMO Capital Markets Rating: Hold New Target: $317.0 Maintain
22/09/2017 Broker: Needham Rating: Hold Maintain
12/09/2017 Broker: Jefferies Rating: Hold New Target: $317.0 Maintain
31/08/2017 Broker: BMO Capital Markets Rating: Hold New Target: $317.0 Maintain
28/07/2017 Broker: Cowen & Co Rating: Hold New Target: $317.0000 Maintain
28/07/2017 Broker: Needham Rating: Hold
10/07/2017 Broker: BMO Capital Markets Rating: Hold New Target: $317.0000 Maintain
29/06/2017 Broker: Jefferies Rating: Hold New Target: $317.0000 Maintain

The stock increased 0.06% or $0.19 during the last trading session, reaching $332.07. About 569,167 shares traded or 16.85% up from the average. C. R. Bard, Inc. (NYSE:BCR) has risen 40.70% since December 7, 2016 and is uptrending. It has outperformed by 24.00% the S&P500.

C. R. Bard, Inc., together with its subsidiaries, designs, makes, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. The company has market cap of $24.21 billion. The firm offers vascular products, such as percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents, and vascular grafts; vena cava filters; biopsy devices; and a range of minimally invasive devices for the treatment of peripheral vascular and end-stage renal diseases. It has a 43.8 P/E ratio. It also provides urology products, including Foley catheters to reduce the rate of urinary tract infections; fecal incontinence products; brachytherapy devices and radioactive seeds for the treatment of prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems; ureteral stents; specialty devices for stone removal procedures; surgical slings and pelvic floor repair products; catheter stabilization devices; and products for therapeutic hypothermia.

More news for C. R. Bard, Inc. (NYSE:BCR) were recently published by: Investorplace.com, which released: “CR Bard (BCR) a Strong Buy on Exceptional Quant Score” on November 28, 2017. Bizjournals.com‘s article titled: “What Jabil’s new director signals about the company’s future” and published on November 30, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.